CF lung disease often begins before the onset of overt clinical symptoms. Objective monitoring of disease progression is challenging, particularly in young children. This symposium will highlight advances in lung function, imaging, metabolomics & biomarkers aimed at detecting early changes in the CF lung.
Review the need for improved, sensitive measures of lung disease in presymptomatic children with CF.
Assess the role of chest imaging & lung clearance index in detection of lung disease in presymptomatic children.
Evaluate the utility of biomarkers in monitoring disease progression in presymptomatic children.